This might be due to several reasons: First, GLP‐1 receptor agonists are similar to other monoagonist therapies for chronic weight management, as they result in a modest 5%–15% weight loss in adults with obesity and/or diabetes (Klonoff et al., 2008; Riddle et al., 2006; Wilding et al., 2021). Here, GLP1R is linked to obesity disorder.